Bio
My Story
Our research includes mechanistic studies of serine proteases, and drug design and discovery. We also conduct structural studies on a variety of topics, often in collaboration with other faculty. Our serine protease studies use NMR and mutagenesis to identify and evaluate key hydrogen bonding and electrostatic interactions within serine protease active sites. The drug discovery efforts focus on the development of a platform technology for discovering new inhibitors of serine protease and the rationale design of "smarter" synthetic agents for modulating disease processes.
Publications
30 Nov 2023 Journal of Nuclear Medicine
DOI: https://doi.org/10.2967/jnumed.123.266345
Joe A.B. McCann and William W. Bachovchin Sarah E. Poplawski, Robin M. Hallett, Mark H. Dornan, Kyle E. Novakowski, Shuang Pan, Anthony P. Belanger, Quang-De Nguyen, Wengen Wu, Albert E. Felten, Yuxin Liu, Shin Hye Ahn, Valerie S. Hergott, Barry Jones, Jack H. Lai
2021 Nov 1;13(21):5495.
doi: 10.3390/cancers13215495.
Henderson JM, Xiang MSW, Huang JC, Wetzel S, Jiang L, Lai JH, Wu W, Kench JG, Bachovchin WW, Roediger B, McCaughan GW, Zhang HE, Gorrell MD
2021 Jan:177:105766.
doi: 10.1016/j.pep.2020.105766. Epub 2020 Sep 25.
Shin J, Phelan PJ, Gjoerup O, Bachovchin W, Bullock PA
Research Projects
About us
BBS technology and programs
1.Tumor Micro-enviroment Activated Drug (TMACs).
A platform technology—currently focused on using FAP as the tumor specific enzyme for activation.
Example: AVA6000 releases Doxorubicin. Currently licensed to Avacta Life sciences and is in phase 1 human clinical trials.
2.Tumor Microenvironment Localized drugs. (TMELDs).
Also platform technology currently focused on using FAP, but exploits binding to FAP rather than activation.
Example: PNT6555. A radiotheranostic licensed to Point Biopharma and currently in phase 1 human clinical trials.
3.Can-SEEK.
FAP activated PSMA or folate receptor targeted Radio theranostics. Ongoing collaboration with Point Biopharma. Lead candidates have been designed and synthesized and currently being characterized.
